Nektar Therapeutics (NKTR) Misses Q1 EPS by 69c, Miss on Revenues

Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.60), $0.69 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $38.02 million versus the consensus estimate of $140.61 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c